Darwin $120 mil. acquisition by Chiroscience combines genomic, chiral technologies.
DARWIN $120 MIL. ACQUISITION BY CHIROSCIENCE WILL COMBINE GENOMIC AND CHIRAL technologies within the Cambridge, U.K.-based drug discovery company. According to the terms of a conditional merger agreement announced Nov. 20, Chiroscience will issue to Darwin Molecular shareholders between 17.4 mil. and 21.3 mil. shares depending on the market price of Chiroscience's shares over a period of 10 days ending Dec. 16.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth